Scotiabank analyst Konark Gupta upgrades Canadian Pacific Railway (TSX:CP) from Sector Perform to Sector Outperform and raises the price target from C$110 to C$116.
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Provention Bio (NASDAQ:PRVB) from Buy to Neutral and raises the price target from $16 to $25.